menu
    • menu
    [{"orgOrder":0,"company":"Modifi Bio","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"MGMT","graph1":"Oncology","graph2":"Preclinical","graph3":"Modifi Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Modifi Bio \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Modifi Bio \/ National Cancer Institute"},{"orgOrder":0,"company":"Modifi Bio","sponsor":"Connecticut Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Modifi Bio","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Modifi Bio \/ Connecticut Innovation","highestDevelopmentStatusID":"4","companyTruncated":"Modifi Bio \/ Connecticut Innovation"},{"orgOrder":0,"company":"Modifi Bio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"MOD-246","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Modifi Bio","amount2":1.3300000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Modifi Bio \/ Merck & Co","highestDevelopmentStatusID":"14","companyTruncated":"Modifi Bio \/ Merck & Co"}]

    Find Clinical Drug Pipeline Developments & Deals by Modifi Bio

    Menu

    Modifi Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Modifi Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Modifi Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MOD-246

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : $1,330.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Modifi Biosciences Acquired by Merck

                            Details : Through the acquisition, Merck will utilize Modifi's scientific expertise and oncology product pipeline, which includes MOD-246, a small molecule currently being evaluated for glioblastoma.

                            Brand Name : MOD-246

                            Molecule Type : Small molecule

                            Upfront Cash : $30.0 million

                            October 23, 2024

                            Lead Product(s) : MOD-246

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : $1,330.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Modifi Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Modifi Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Connecticut Innovation

                            Deal Size : $10.7 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Modifi Bio Raises Additional $4.3 Million in Seed Funding

                            Details : The financing will be used to further advance Modifi bio's lead molecules towards IND-enabling studies and phase I clinical trials. It works in DNA modification as a novel approach to target cancer.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 16, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Connecticut Innovation

                            Deal Size : $10.7 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Modifi Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Modifi Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : National Cancer Institute

                            Deal Size : $2.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Modifi Bio Receives $2.4 Million Award from National Cancer Institute to Advance Innovative Precision Oncology...

                            Details : The grant will support drug development around a class of molecules targeting cancer cells lacking expression of key DNA repair protein called MGMT (O6-methylguanine methyl transferase), based on a recent publication from the Yale founders’ laboratorie...

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 25, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : National Cancer Institute

                            Deal Size : $2.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth